Five-Year Survival Results of Subcutaneous Low-Dose Immunotherapy with Interleukin-2 Alone in Metastatic Renal Cell Cancer Patients

Publisher： Karger

E-ISSN： 1423-0399|64|1|3-8

ISSN： 0042-1138

Source： Urologia Internationalis, Vol.64, Iss.1, 2000-04, pp. : 3-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Chronically Administered Immunotherapy with Low-Dose IL-2 and IFN-α in Metastatic Renal Cell Carcinoma: A Feasible Option for Patients with a Good Prognostic Profile

By  

Oncology, Vol. 76, Iss. 1, 2008-12 ,pp. : 69-76

Karger

Access to resources Recommend Favorite

Clinical and Safety Profile of High-Dose Interleukin-2 Treatment in Elderly Patients with Metastatic Melanoma and Renal Cell Carcinoma

By  

Oncology, Vol. 84, Iss. 2, 2012-12 ,pp. : 123-126

Karger

Access to resources Recommend Favorite

An Outpatient Phase II Study of Subcutaneous Interleukin-2 and Interferon-Alpha-2b in Combination with Intravenous Vinblastine in Metastatic Renal Cell Cancer

By  

Oncology, Vol. 55, Iss. 1, 1997-12 ,pp. : 10-15

Karger

Access to resources Recommend Favorite

Immunotherapy with histamine dihydrochloride and low‐dose interleukin‐2 favors sustained lymphocyte recovery in acute myeloid leukemia

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 3, 2015-03 ,pp. : 279-280

John Wiley & Sons Inc

Access to resources Recommend Favorite

METASTATIC CARCINOMA OF THE OVARY: REPORT OF A CASE WITH FIVE‐YEAR SURVIVAL

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 11, Iss. 1, 1963-01 ,pp. : 90-95

John Wiley & Sons Inc

Access to resources Recommend Favorite